The panel also asked the Ministry to make "earnest" efforts for finalisation of rates of proposed 1165 drugs for inclusion in the generic formulary.
The parliamentary committee also asked the Ministry to establish an effective centralised mechanism to periodically monitor the quality of generic drugs to provide good quality generic drugs throughout the country while asserting that international benchmark should be followed.
The Public Accounts Committee of the Ministry of Health on "procurement of allopathic drugs in CGHS" in its 52nd report said that it "regrets" to note that inspite of lapse of six years, no concrete system has been put in place to effectively deal with the issue of complete switch towards generic medicines.
"The Ministry should also establish an effective centralised mechanism to periodically monitor the quality of generic drugs so as to provide good quality generic drugs throughout the country. International benchmark may also be followed in this regard," the panel chaired by K V Thomas, said in its report.
The committee noted that in September 2010, the Health Ministry while approving the revised formulary of branded drugs had directed for complete shift towards generic drugs within one year both in prescriptions and supplies.
the Ministry do not mention about steps taken on these aspects. Rather they have expressed that it might take some time before beneficiaries and doctors are persuaded to depend largely on generic medicines.
"The committee regret to note that inspite of lapse of six years since the Minister's statement, no concrete system has been put in place as yet to effectively deal with the issue of complete switch over towards generic medicines," the committee said.
The committee also took "serious" note of the failure of the Health Ministry to apprise it on the findings of the committee set up under DG (Health Services) and action taken by the Ministry.
"The committee feel that in order to augment the procurement of generic drugs, Ministry should take earnest efforts for finalisation of rates of drugs and apprise the committee of the same within two months of the presentation of the report," the committee said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
